Search for information about a product,
therapeutic area or event

Media, investors, advocacy organizations and others, please contact us here.

group of people

Efficacy and Safety of Sparsentan Versus Irbesartan
in Patients With IgA Nephropathy (PROTECT):
2-year Results From a Randomised,
Active-Controlled, Phase 3 Trial

Journal article
Published on November 3, 2023

Topics: Nephrology IgAN Sparsentan PROTECT Clinical Infographic Publication Summary Video

Contributors:
Rovin BH, Barratt J, Heerspink HJL et al.
Name of Journal:
The Lancet


View Publication
DOI:
10.1016/S0140-6736(23)02302-4
Share:


Home » Publications » PROTECT Phase 3 Trial

About the PROTECT trial

Background

  • IgA nephropathy is a rare kidney disease. It can lead to progressive kidney function decline and kidney failure within 10 to 20 years of diagnosis1,2
  • Endothelin-1 (ET-1) and angiotensin II (Ang II) are two critical peptides that act in tandem and are responsible for the progression of IgA nephropathy over time3,4
  • Sparsentan is an FDA approved non-immunosuppressive, single-molecule, Dual Endothelin Angiotensin Receptor Antagonist (DEARA) indicated to slow kidney function decline in adults with primary IgA nephropathy who are at risk for disease progression5,6

Aim

The PROTECT study evaluates long-term efficacy and safety of sparsentan versus irbesartan in IgA nephropathy6

PROTECT: A large, international, randomized,
double-blind, active controlled Phase 3 trial

Flow diagram shows the Phase 3 PROTECT trial design: patients from 134 sites in 18 countries were randomly assigned to the sparsentan treatment group or active-control irbesartan group. The study included a 110-week double-blind period with an interim analysis at 36 weeks and 2-year follow-up at 110 weeks, 4 weeks of no treatment, and a 156-week open-label extension period

Key findings

Decorative image

Sparsentan met its primary endpoint showing superior reductions in proteinuria from baseline to Week 36 versus irbesartan. This reduction was sustained over 2 years5-7

Decorative image

The absolute LS mean change in eGFR from baseline to Week 110 was smaller with sparsentan versus irbesartan, demonstrating a greater preservation of kidney function with sparsentan5,6

Decorative image

The safety profile of sparsentan is comparable with that of irbesartan5,6

Decorative image

The most common AEs with sparsentan were hyperkalemia, hypotension, peripheral edema, dizziness, anemia, acute kidney injury, and transaminase elevations5‡

Most common AEs are per the FDA US Prescribing Information

Decorative image

There were no instances of drug-induced liver injury or discontinuations due to heart failure or edema6

Resources

Downloadable Resource
Nephrology
Infographic of the Phase 3 PROTECT study

Learn more about the two-year findings from PROTECT

View infographic
Downloadable Resource
Nephrology
Plain language summary of the Phase 3 PROTECT study

Explore the PROTECT two-year findings plain language summary

View the PROTECT PLS

Conclusions

Sparsentan demonstrated5,6:

Superior reductions in proteinuria
Better preservation of kidney function that accrued year on year
A comparable safety profile with irbesartan
Illustration of a group of people

Projected eGFR data of sparsentan and irbesartan suggest prolonged kidney survival with sparsentan6

*Participants were enrolled between December 2018 and May 2021.6 Includes related terms.5 Elevations in ALT or AST greater than 3-fold ULN.5

AE, adverse event; ALT, alanine aminotransferase; Ang II, angiotensin II; AST, aspartate aminotransferase; AT1R, angiotensin II subtype 1 receptor; DEARA, Dual Endothelin Angiotensin Receptor Antagonist; eGFR, estimated glomerular filtration rate; ET-1, endothelin 1; ETAR, endothelin type A receptor; FDA, Food and Drug Administration; 
IgA, immunoglobulin A; ULN, upper limit of normal; UPCR, urine protein-creatinine ratio.

  1. Kwon CS et al. J Health Econ Outcomes Res. 2021;8(2):36-45.
  2. Pitcher D et al. Clin J Am Soc Nephrol. 2023;18(6):727-738.
  3. Martínez-Díaz I et al. Int J Mol Sci. 2023;24(4):3427.
  4. Komers R, Plotkin H. Am J Physiol Regul Integr Comp Physiol. 2016;310(10):R877-884.
  5. FILSPARI® (sparsentan) Prescribing Information. San Diego, CA: Travere Therapeutics, Inc.
  6. Rovin BH et al. Lancet. 2023;402(10417):2077-2090.
  7. Heerspink HJL et al. Lancet. 2023;401(10388):1584-1594.

MA-SP-24-0049 | October 2025